POLARIS: efficacy and safety of a vaginal medical device in recurrent bacterial vaginosis—a multicenter, open-label, non-controlled, study with 10 months of follow-up

Recurrent bacterial vaginosis (RBV) after antibiotic treatment has relapse rates of 35% within 3 months and 60% within 12 months. A medical device containing polycarbophil, lauryl glucoside, and glycerides (PLGG) inhibits bacterial growth and has mucoadhesive properties. This study examined the efficacy of the device in women with RBV.